🇪🇺 VYEPTI in European Union

EMA authorised VYEPTI on 24 January 2022

Marketing authorisation

EMA — authorised 24 January 2022

  • Application: EMEA/H/C/005287
  • Marketing authorisation holder: H. Lundbeck A/S
  • Local brand name: Vyepti
  • Indication: Vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
  • Status: approved

Read official source →

VYEPTI in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in European Union

Frequently asked questions

Is VYEPTI approved in European Union?

Yes. EMA authorised it on 24 January 2022.

Who is the marketing authorisation holder for VYEPTI in European Union?

H. Lundbeck A/S holds the EU marketing authorisation.